Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) was up 13.3% during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. Finally, Wall Street Zen raised Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Autolus Therapeutics Stock PerformanceThe stock has a market cap of $614.03 million, a P/E ratio of -2.12 and a beta of 2.07. Further ReadingReceive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.